Compare ARK Genomic Revolution ETF (ARKG) vs Verisign, Inc. (VRSN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Verisign, Inc. — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while Verisign, Inc. trades at $273.48 (market cap $24.58B). The key difference: Verisign, Inc. pays a 1.2% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Verisign, Inc. nearer its low. Which is the better fit depends on your goals.
| ARKG | VRSN | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $310.00 |
52-Week Low | $23.09 | $211.49 |
Market Cap | — | $24.58B |
Enterprise Value | — | $25.82B |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
VeriSign (VRSN) trades at $270.11, up 0.05% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $327.67. The company reported Q1 2026 EPS of $2.34, beating expectations, and maintains strong profitability with a net income margin near 50%. Recent news highlights AI-driven domain registration growth and the upcoming Q2 2026 earnings report on July 23, 2026.
The outlook for VRSN is positive, supported by stable revenue growth, high margins, and analyst optimism, but risks include AI disruption to its domain business, contract renewals, and a high debt load. The stock offers potential upside to the consensus target, though investors should monitor earnings execution and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
